Xlife Sciences AG

  • ISIN: CH0461929603
  • Land: Schweiz

Nachricht vom 16.05.2022 | 07:05

Project company Xsight Optics successfully participates in start-up competition – prize money finances relevant R&D project

Xlife Sciences AG / Key word(s): Miscellaneous
Project company Xsight Optics successfully participates in start-up competition – prize money finances relevant R&D project
16.05.2022 / 07:05

Xsight Optics, based in Jena (Germany), a project company of Xlife Sciences AG (SIX: XLS), has successfully participated in this year's StartUp competition “get started 2gether” organized by the Thuringia Research and Technology Association and the Thuringia Ministry of Economics: The company won funding for a relevant new research and development project, and was also awarded the audience prize.

Xsight Optics' vision is to expand human-centered, digital care. To this end, the company is developing a portable optical sensor with which medical staff in hospitals and care facilities can, for example, record the heart rate, oxygen saturation, temperature, and respiratory rate of patients from a safe distance without contact (and transfer them directly to an already existing Documentation system).

This mobile sensor derives these health parameters from several image properties through a clever combination of optical technology, microelectronics, and AI-supported algorithms. Central to this is secure and reliable imaging software. The awarded prize money of EUR 80,000 will enable Xsight Optis to finance a corresponding R&D project with the Intelligent Systems Department of the Institute for Applied Building Research Weimar.

Oliver R. Baumann, CEO of Xlife Sciences, comments: “We warmly congratulate CEO Maria Nisser and CSO Jan Sperrhake of our project company Xsight Optics for their doubly successful pitch at the renowned Thuringian StartUp funding award “get started 2gether”. The funding thus achieved for the interdisciplinary research and development project with the experts in computer vision and data analysis from the Institute for Applied Building Research Weimar is a relevant milestone for Xsight Optics' endeavor to expand human-centered, digital care.”


Financial calendar

Ordinary General Assembly 2022            June 20, 2022

2022 Half-Year Results                              September 28, 2022



Information for journalists: IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch

Information for investors: Xlife Sciences AG, Dennis Lennartz, dennis.lennartz@xlifesciences.ch

Xlife Sciences AG
Talacker 35
8001 Zürich
Telefon: 0041 44 385 84 60
ISIN: CH0461929603
Börsen: SIX Swiss Exchange  

About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch


Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.

End of Media Release

show this

GBC im Fokus

Landi Renzo: GBC-Interview mit CEO Christiano Musi

„Der Landi Renzo-Konzern ist ein globaler Akteur, der sich auf die Energiewende entlang der gesamten Wertschöpfungskette spezialisiert hat und darauf abzielt, ein weltweiter Referenzpunkt für RNG- und Wasserstoffanwendungen bei Green Mobility und Clean-Tech-Lösungen zu werden. Bis 2025 erwarten wir Umsatzzuwächse von 15% (CAGR) und ein zweistelliges EBITDA-Wachstum von 25% (CAGR), dank ansteigender Umsätze in Segmenten, die im Vergleich zu unserem traditionellen Markt für leichte Nutzfahrzeuge höhere Margen aufweisen."

Events im Fokus

Termine 2022

12./13. Oktober 2022: Fachkonferenz Finanzdienstleistungen/Technologie

News im Fokus

Henkel AG & Co. KGaA: Henkel steigert Umsatz deutlich, treibt strategische Agenda voran und hebt Umsatzprognose für 2022 an

15. August 2022, 07:30

Aktueller Webcast

HomeToGo SE

Webcast Link

16. August 2022

Aktuelle Research-Studie


Original-Research: Apontis Pharma AG (von Montega AG): Kaufen

16. August 2022